KLF11 Is a Novel Endogenous Protectant against Renal Ischemia-Reperfusion Injury.

Autor:	Nath KA; Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, Minnesota., Singh RD; Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, Minnesota., Croatt AJ; Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, Minnesota., Ackerman AW; Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, Minnesota., Grande JP; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota., Khazaie K; Department of Immunology, Mayo Clinic, Phoenix, Arizona., Chen YE; Department of Internal Medicine, Cardiovascular Center, University of Michigan Medical Center, Ann Arbor, Michigan., Zhang J; Department of Internal Medicine, Cardiovascular Center, University of Michigan Medical Center, Ann Arbor, Michigan.
Jazyk:	angličtina
Zdroj:	Kidney360 [Kidney360] 2022 May 06; Vol. 3 (8), pp. 1417-1422. Date of Electronic Publication: 2022 May 06 (Print Publication: 2022).
DOI:	10.34067/KID.0002272022
Abstrakt:	Discovering new nephroprotectants may provide therapeutic strategies in AKI.This study provides the first evidence that KLF11, a member of the Krüppel-like factor (KLF) family of proteins, protects against AKI.In the absence of KLF11, exaggerated induction of endothelin-1 and IL-6 occurs after ischemic renal injury and may contribute to worse AKI. Competing Interests: J.P. Grande reports being a member of the editorial board for Biochemistry and Molecular Biology Education Journal. K.A. Nath reports an advisory or leadership role for the Journal of the American Society of Nephrology and Mayo Clinic Proceedings. All remaining authors have nothing to disclose. (Copyright © 2022 by the American Society of Nephrology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu